Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on industrializing drug discovery through a unique, technology-driven approach. The company leverages a sophisticated platform that integrates artificial intelligence, automation, and high-throughput screening to decode complex biological and chemical interactions. This allows Recursion to rapidly identify and develop novel therapeutics across a range of challenging diseases. Their pipeline includes several promising drug candidates in various stages of clinical development, targeting conditions such as cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, and specific types of cancer. Recursion's business model emphasizes a data-centric strategy, generating vast amounts of biological data that are analyzed by their proprietary AI algorithms to accelerate the identification of potential drug targets and candidates. The company has established strategic collaborations with major pharmaceutical players like Bayer, Roche & Genentech, and Takeda, as well as academic institutions, underscoring the broad applicability and potential of its platform. By building a comprehensive understanding of disease biology at scale, Recursion aims to significantly reduce the time and cost associated with traditional drug development, ultimately bringing innovative treatments to patients more efficiently.